Amanta Healthcare Limited (AMANTA) fundamentals
Amanta Healthcare Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as AMANTA (ISIN INE084K01015). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Amanta Healthcare Limited does
Amanta Healthcare Ltd is an India-based pharmaceutical company. The Company is engaged in developing, manufacturing and marketing a diverse range of sterile liquid products-parenteral products, being packed in plastic containers with Aseptic Blow-Fill-Seal (ABFS) and Injection Strech Blow Molding (ISBM) technology. The Company manufactures large volume parenteral (LVPs) and small volume parenteral (SVPs) in six therapeutic segments. In addition to that, it also manufactures medical devices. The Company manufactures fluid therapy- (IV Fluid), formulations, diluents, ophthalmic, respiratory care and irrigation solutions in the therapeutic segment and products like irrigation, first-aid solutions, eye lubricants in the medical device segment. It also offers a various range of closure systems, such as nipple head, twist-off, leur-lock and screw types and container fill-volume ranging from two milliliters (ml) to 1000 ml.
Valuation and market data
| Last close | ₹197.75 |
|---|---|
| Market capitalisation | ₹680 crore |
| Enterprise value | ₹795 crore |
| P/E (TTM) | 45.67 |
| Price to book | 3.09 |
| Price to sales (TTM) | 1.35 |
| Book value per share | ₹64.08 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Tue Sep 09 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹291 crore | ₹21 crore | ₹15 crore | 4.33 |
| Mar 2025 | ₹276 crore | ₹15 crore | ₹11 crore | 3.71 |
| Mar 2024 | ₹282 crore | ₹5 crore | ₹4 crore | 1.35 |
| Mar 2023 | ₹263 crore | ₹3 crore | ₹-2 crore | -0.79 |
| Mar 2022 | ₹227 crore | ₹62 crore | ₹55 crore | 20.54 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 63.8% |
|---|---|
| Foreign institutions (FII) | 0.4% |
| Mutual funds | 5.3% |
| Other domestic institutions | 7.6% |
| Retail and others | 22.9% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.